TCON News and Press, TRACON Pharmaceuticals Inc. From 03/18/21

The following slide deck was published by TRACON Pharmaceuticals, Inc. in conjunction with this event. For further details see: TRACON Pharmaceuticals (TCON) Investor Presentation - Slideshow

I-MAB BioPharma is a new player in the global pharmaceuticals market with autoimmune products. It has a robust portfolio of marketable drugs with several more in the pipeline. The company has global partnerships and an international footprint that will expand drastically as its ne...

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. comp...

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...

Tracon Pharmaceuticals shares are up ~400% since the beginning of September 2020, owing to excitement surrounding its lead asset, subcutaneously administrated envafolimab. This recent runup still places the stock down ~90% from its 2014 IPO price. With somewhat de-risked data from...

TRACON Pharmaceuticals, Inc. (TCON) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Charles Theuer - CEO Scott Brown - CFO Conference Call Participants Maury Raycroft - Jefferies Jason McCarthy - Maxim Group Bert Hazlett - BTIG Presentation Operator Good day...

Tracon (TCON): Q4 GAAP EPS of -$0.31 beats by $0.10.Cash, cash equivalents and short-term investments were $36.1M at year end. Press Release For further details see: Tracon EPS beats by $0.10

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...